Navigation Links
Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information
Date:12/18/2007

- PAH Pathways(TM) Program offers Patient Support and Financial Assistance

-

SOUTH SAN FRANCISCO, Calif., Dec. 18 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc. today announced results of a recent Harris Interactive(R) survey, showing that an overwhelming majority of Tracleer patients enrolled in Sure Steps find the patient support program valuable, and feel that their knowledge of pulmonary arterial hypertension (PAH) and Tracleer have improved due to the program. The Sure Steps program, part of Actelion's PAH Pathways(TM) service and support program, is a support and education program available to all PAH patients on Actelion's PAH products, Tracleer and Ventavis(R) (iloprost) Inhalation Solution.
Key findings from the survey of patients enrolled in Sure Steps show that:

-- Nine in ten (89 percent) enrolled patients are satisfied with the

program;

-- Almost all (97 percent) would recommend the program to other PAH

patients on Tracleer;

-- Six out of seven (85 percent) enrolled patients are more comfortable

discussing their PAH therapy with their physicians because of the

program; and

-- 92 percent feel better informed about Tracleer as a result of

information provided in the program.

The survey was conducted by Harris Interactive on behalf of Actelion between August 7 and August 21, 2007. It included more than 600 patients currently enrolled in Sure Steps, 256 of whom who had been on Tracleer for less than one year, and 354 patients who had been on Tracleer for more than a year. All patients were 18 year of age or older, diagnosed with PAH, currently taking Tracleer, and had been enrolled in the Sure Steps program for at least two months.

"When patients are first diagnosed with PAH and begin treatment, they are often overwhelmed by their diagnosis and have many questions about treatment," said Craig Hopkinson, MD, Vice
'/>"/>

SOURCE Actelion Pharmaceuticals US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
2. International Survey Shows People Over Forty Ignore Risk of Blindness
3. 2007 Global Survey Identifies Characteristics of Supply Chain Leaders
4. Survey Sees Mass. CEOs as Bullish on Own Businesses
5. Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey
6. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
7. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
(Date:1/22/2015)... 2015  Derma Sciences, Inc. (Nasdaq: DSCI ... wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic ... to the Premier, Inc. Regenerative Skin Grafting contract ... AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue to ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... Boston, MA (PRWEB) December 23, 2014 Earlier ... James L. Sherley, director of the Adult Stem Cell Technology ... overlooked and under appreciated unique property of adult tissue stem ... Misunderstood in the Past, Important for the Future,” embodied the ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... PDE10 Collaboration with Amgen- ... Call at 9:00 A.M. EDT-, MONTVALE, N.J., March ... announced that it has realigned,its operations, reallocated its resources ... with Amgen. The Company will,focus its near-term and mid- ...
... for Healthcare Industry by ... Identifying Eight Herpesviruses Simultaneously, HELSINKI, Finland, March ... the new Prove-it(TM) Herpes,test for the fast and ... than three hours to complete and enables,simultaneous identification ...
... Nile Therapeutics,Inc. (OTC Bulletin Board: NILT), today announced that ... for 2007 after the market,closes on Thursday, March 13, ... webcast to discuss these financial results and provide an,update ... ET, 1:30 p.m. PT,that afternoon., Interested investors may ...
Cached Biology Technology:Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 2Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 3Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 4Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 5Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification 2Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008 2
(Date:1/22/2015)... 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), the ... campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz will ... capacity to meet customer demand. Logo ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by Dr. ...
(Date:1/22/2015)... N.C. , Jan. 16, 2015  A man-made form ... memory and other mental capabilities in adults with mild ... pilot study led by researchers at Wake Forest Baptist ... adults diagnosed with amnesic mild cognitive impairment (MCI) or ...
(Date:1/22/2015)... Issued by Small Cap IR. In 2011, Nilson Report,s annual ... merchants on the leading payment cards rose to $135.3 billion ... prepaid cards reached 6.54 billion.  Eight million credit card users ... 2012, and credit and debit card fraud resulted in $11.27 ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... waste occupying our landfills has grown at an alarming rate ... toxicity of components used in consumer electronics. Researchers ... minimize environmental hazards associated with a material likely to play ... in the future. The results of their most recent studies ...
... colorful wings, the future of Monarch butterflies may not be ... down again this year, says a Texas A&M University researcher. ... the Center for Mathematics and Science Education and a long-time ... donors and Mexico,s Michoacan state show that Monarch numbers will ...
... poll* of more than 10,000 citizens from ten European countries, ... among all issues that threaten the marine environment. A new ... concern is not misplaced and is supported by scientific evidence. ... market have a production volume higher than one tonne per ...
Cached Biology News:UF researchers look for ways to make an emerging technology safe for environment 2Monarch butterflies down again this year as decline continues, says Texas A&M expert 2Chemical pollution in Europe's seas: The monitoring must catch up with the science 2
... histochemically detect specific senescence ... in cultured cells and ... marker is only present ... found in presenescent/quiescent/immortal cells. ...
TAR DNA binding protein...
... Star strains are high-performance ... improved protein yield in ... (Figure 1). Because the ... mRNA more rapidly than ...
...
Biology Products: